Intermediate Filament-Derived Peptides for Vaccine Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants used in vaccines, such as PAMPs, aluminium hydroxide, and MF59, induce excessive inflammation and systemic adverse effects, and are inefficient in stimulating Th1 CD4+ and cytotoxic CD8+ T-lymphocyte responses, limiting their effectiveness against intracellular infections.
Innovation Solution
Peptides derived from intermediate filaments, specifically with a defined amino acid sequence, induce apoptosis, pyroptosis, and necroptosis in eukaryotic cells, and stimulate pro-inflammatory cytokine secretion, making them potential new adjuvants for vaccines and chemotherapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PAMPs are used as adjuvants, then antibody production is stimulated, but excessive local inflammation and systemic adverse effects occur
Solution Approach 1:
The patent extracts the essential adjuvant function from traditional PAMPs by identifying and isolating specific peptide sequences derived from intermediate filaments. These peptides retain the ability to stimulate antibody production and T-cell responses while eliminating the harmful inflammatory effects associated with conventional PAMPs, achieving functional separation of beneficial and harmful properties
Solution Approach 2:
The patent changes the molecular parameters of the adjuvant by using synthetic peptides with specific amino acid sequences (9-50 amino acids) derived from intermediate filaments. This parameter change transforms the adjuvant from traditional PAMPs to a new class of peptide-based adjuvants that modulate immune responses more precisely, reducing harmful inflammation while maintaining protective antibody production
2Quantity of substance
If aluminium hydroxide or MF59 are used as adjuvants, then blocking antibody production is stimulated, but Th1 CD4+ and cytotoxic CD8+ T-lymphocyte responses are not efficiently stimulated
Solution Approach 1:
The patent creates a multi-functional adjuvant system using intermediate filament-derived peptides that simultaneously stimulate multiple immune response types. The peptides can induce both antibody production and T-cell responses (Th1 CD4+ and cytotoxic CD8+) depending on the peptide sequence and delivery context, allowing a single adjuvant to perform multiple immune-stimulating functions that were previously achieved by separate agents
Solution Approach 2:
The patent employs composite peptide structures combining specific amino acid motifs (including hydrophobic regions, charged residues, and repetitive sequences) to create adjuvants with enhanced immunostimulatory capacity. These composite peptide designs enable coordinated activation of B-cell, Th1, and CD8+ T-cell pathways, achieving a composite immune response that addresses both antibody production and cell-mediated immunity
3Quantity of substance
If conventional adjuvants are used, then immune response is stimulated, but effectiveness against intracellular infections is limited
Solution Approach 1:
The patent inverts the traditional adjuvant approach by using endogenous intermediate filament peptides rather than exogenous pathogen-derived or synthetic adjuvants. This inversion allows the adjuvant to leverage the body's own cellular components to trigger immune responses, creating a more physiological and effective stimulation that better targets intracellular pathogens through enhanced Th1 and cytotoxic T-cell activation
Data Source
AI summary
The present invention relates to peptides derived from known intermediate filaments which are capable of inducing cell death in metazoan cells, and/or stimulating pro-inflammatory cytokine secretion. The peptides consist of a first region of “n” amino acids, wherein “n” is 0 to 41 amino acids; a second region of 9 amino acids; wherein the sequence of 9 amino acids is [(a)/(b)]-[K/R]-[(a)/(b)]-[(a)/(b)/(c)/(d)]-[L]-[(e)]-[(a)/(b)/(c)]-[E]-[I] (SEQ ID NO: 1), wherein (a) is a nonpolar aliphatic amino acid, (b) is a polar uncharged amino acid, (c) is a positively charged amino acid, (d) is an aromatic amino acid, (e) is a negatively charged amino acid; and a third region of “m” amino acids, wherein “m” is 0 to 41 amino acids. The peptides of the invention have a minimum length of 9 amino acids and a maximum length of 50 amino acids. These peptides may be useful as new adjuvants in vaccines, either alone or in combination with other therapies; as well as chemotherapeutic agents, either alone or in combination with other drugs or therapies.